Investors

Edesa Biotech – Corporate Overview

We are a biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. We have multiple late-stage product candidates in our development pipeline in the fields of respiratory diseases and medical dermatology.

Our most advanced respiratory drug candidate is EB05 (paridiprubart). EB05 represents a new class of therapies called Host-Directed Therapeutics (HDTs) that are designed to modulate the body’s own immune response when confronted with infectious diseases or even chemical agents. EB05 is being evaluated in a U.S. government-funded Phase 2 platform study of HDTs. We have also been awarded Canadian government funding to support this development program. In addition, we are preparing an IND for a future Phase 2 study of paridiprubart in patients with pulmonary fibrosis.

In dermatology we are developing EB06, an anti-CXCL10 monoclonal antibody, as therapy for vitiligo. CXCL10 has been shown to play both a key role in the disease and neutralization of CXCL10 has been demonstrated to both prevent and reverse depigmentation in animal models. Our derm program also includes EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for Allergic Contact Dermatitis, a common occupational skin condition.